Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Gains from Sales and Divestitures (2023 - 2024)

Mereo BioPharma (MREO) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Sales and Divestitures rose 166.89% to $1.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.3 million, a 166.89% increase, with the full-year FY2024 number at $1.3 million, up 166.89% from a year prior.
  • Gains from Sales and Divestitures was $1.3 million for Q4 2024 at Mereo BioPharma, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q3 2024 to a low of $142583.0 in Q1 2024.